Please assess the completion status of the following clinical trial:

Trial Title: Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension stage II~* Male and female patients~* Age \>= 18 years old~Exclusion Criteria:~* Severe hypertension (systolic BP \>= 180 mmHg, diastolic BP \>= 110 mmHg~* Poorly controlled diabetes mellitus or type 1 DM~* History of myocardial infarction, stroke~* Presence of heart failure~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non responder Olmesartan/Amlodipine (Type: EXPERIMENTAL): Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ

Based on this trial design, predict the completion outcome and termination type (if applicable).